CHF5993

DRUG2 trials

Sponsors

Chiesi Farmaceutici S.p.A.

Conditions

AsthmaChronic Obstructive Pulmonary DiseaseChronic Obstructive Pulmonary Disease (COPD)

Phase 1

A Thorough QT (TQT) Study of CHF5993 pMDI in Healthy Volunteers (HV)

CompletedNCT05830071

Chiesi Farmaceutici S.p.A.Asthma, Chronic Obstructive Pulmonary Disease (COPD)

Start: 2023-03-29End: 2023-10-13Updated: 2024-09-04

Phase 4

CHF5993 and CHF1535 pMDI on Lung Hyperinflation and Exercise Endurance Time in Subjects With COPD

CompletedNCT05097014

Chiesi Farmaceutici S.p.A.Chronic Obstructive Pulmonary Disease

Start: 2021-10-28End: 2023-02-24Updated: 2023-03-24

Related Papers

Effects of inhaled beclometasone dipropionate/formoterol fumarate/glycopyrronium vs. beclometasone dipropionate/formoterol fumarate and placebo on lung hyperinflation and exercise endurance in chronic obstructive pulmonary disease: a randomised controlled trial.

2024-10-17